Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-20

Reporting Person: Vivo Capital VIII, LLC (10% Owner)
Reporting Person: Vivo Capital, LLC (10% Owner)
Reporting Person: Vivo Capital Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Capital Surplus Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Opportunity, LLC (10% Owner)
Reporting Person: Vivo Opportunity Fund, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-20	Common Stock	C	2560613	—	Acquired	2560613	Indirect
2018-07-20	Common Stock	C	353590	—	Acquired	353590	Indirect
2018-07-20	Common Stock	C	413040	—	Acquired	2973653	Indirect
2018-07-20	Common Stock	C	57035	—	Acquired	410625	Indirect
2018-07-20	Common Stock	P	51686	$17.00	Acquired	3025339	Indirect
2018-07-20	Common Stock	P	7137	$17.00	Acquired	417762	Indirect
2018-07-20	Common Stock	P	141177	$17.00	Acquired	141177	Indirect
2018-07-20	Common Stock	P	153180	$20.73	Acquired	294357	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-20	Series A Preferred Stock	$	C	8424416	Disposed		Common Stock (2560613)	Indirect
2018-07-20	Series A Preferred Stock	$	C	1163311	Disposed		Common Stock (353590)	Indirect
2018-07-20	Series B Preferred Stock	$	C	1358903	Disposed		Common Stock (413040)	Indirect
2018-07-20	Series B Preferred Stock	$	C	187648	Disposed		Common Stock (57035)	Indirect

Footnotes

F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F3: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F4: These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").

F5: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

F6: Vivo Opportunity, LLC is the general partner of VOF. Vivo Capital LLC is the management company of Vivo Opportunity, LLC. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

F7: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $24.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.